DE602004001393T2 - Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung - Google Patents

Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung Download PDF

Info

Publication number
DE602004001393T2
DE602004001393T2 DE602004001393T DE602004001393T DE602004001393T2 DE 602004001393 T2 DE602004001393 T2 DE 602004001393T2 DE 602004001393 T DE602004001393 T DE 602004001393T DE 602004001393 T DE602004001393 T DE 602004001393T DE 602004001393 T2 DE602004001393 T2 DE 602004001393T2
Authority
DE
Germany
Prior art keywords
solution
emulsion
sphingolipid
dihydrosphingosine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004001393T
Other languages
German (de)
English (en)
Other versions
DE602004001393D1 (de
Inventor
James Barry Pasadena MAURER
C. Patrick Sherman Oaks REYNOLDS
B. Rao Rockville VISHNUVAJJALA
Shanker Rockville GUPTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Children's Hospital of Los Angeles
Childrens Hospital Los Angeles Research Institute
Original Assignee
Children's Hospital of Los Angeles
Childrens Hospital Los Angeles Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Hospital of Los Angeles, Childrens Hospital Los Angeles Research Institute filed Critical Children's Hospital of Los Angeles
Publication of DE602004001393D1 publication Critical patent/DE602004001393D1/de
Application granted granted Critical
Publication of DE602004001393T2 publication Critical patent/DE602004001393T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602004001393T 2003-02-21 2004-02-19 Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung Expired - Lifetime DE602004001393T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44953603P 2003-02-21 2003-02-21
US449536P 2003-02-21
PCT/US2004/004960 WO2004075834A2 (en) 2003-02-21 2004-02-19 Stabilized pharmaceutical compositions of safingol and methods of using the same

Publications (2)

Publication Number Publication Date
DE602004001393D1 DE602004001393D1 (de) 2006-08-10
DE602004001393T2 true DE602004001393T2 (de) 2007-06-14

Family

ID=32927531

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004001393T Expired - Lifetime DE602004001393T2 (de) 2003-02-21 2004-02-19 Stabile pharmazeutische zusammensetzung mit safingol und verfahren zu dessen verwendung

Country Status (9)

Country Link
US (1) US7476692B2 (cg-RX-API-DMAC10.html)
EP (1) EP1594488B1 (cg-RX-API-DMAC10.html)
JP (2) JP4842800B2 (cg-RX-API-DMAC10.html)
AT (1) ATE331507T1 (cg-RX-API-DMAC10.html)
CA (1) CA2516399C (cg-RX-API-DMAC10.html)
DE (1) DE602004001393T2 (cg-RX-API-DMAC10.html)
ES (1) ES2270347T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA05008860A (cg-RX-API-DMAC10.html)
WO (1) WO2004075834A2 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013016B8 (en) 2006-03-29 2014-10-08 Wayne State University Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
CA2817198C (en) * 2009-11-12 2018-05-01 Texas Tech University Compositions and methods for treating hyperproliferative disorders
WO2015013566A1 (en) * 2013-07-25 2015-01-29 Nemucore Medical Innovations, Inc. Nanoemulsions of hydrophobic platinum derivative
IT201600105201A1 (it) * 2016-10-19 2018-04-19 Nutrilinea Srl Uso della fosfatidilserina per la prevenzione e il trattamento dei disturbi della prostata e relative composizioni farmaceutiche e nutraceutiche
US10034895B2 (en) * 2017-11-30 2018-07-31 Joel Steven Goldberg Local application of D-lactic acid dimer is selectively cytotoxic when applied to cancer cells

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716589A4 (en) * 1993-07-23 1997-06-11 Morris Herstein COSMETIC COMPOSITION STIMULATING THE RENEWAL OF THE SKIN WITH A PROLONGED IRRITATION ELIMINATION EFFECT
CA2234968A1 (en) * 1995-10-18 1997-04-24 Mary Kay Inc. Topically applied, structural cellulite treatments
US5635536A (en) 1994-12-07 1997-06-03 Pharmacia & Upjohn Aktiebolag Emulsion suitable for administering a sphingolipid
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
US6352844B1 (en) * 1998-06-29 2002-03-05 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
JP3220434B2 (ja) 1998-12-28 2001-10-22 花王株式会社 化粧料
KR100343885B1 (ko) * 1999-07-20 2002-07-19 주식회사 두산 파이토스핑고신의 수용액의 제조 방법
KR100371491B1 (ko) * 1999-07-27 2003-02-07 주식회사 두산 피부 보호용 크림조성물
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
JP3896234B2 (ja) * 1999-12-24 2007-03-22 花王株式会社 化粧料
EP1287815A1 (en) * 2001-08-31 2003-03-05 Cosmoferm B.V. Use of a sphingoid base for inhibiting ceramidase activity
US7846969B2 (en) 2001-12-10 2010-12-07 Kao Corporation Ceramide emulsions
JP4119646B2 (ja) * 2001-12-10 2008-07-16 花王株式会社 セラミド類乳化物の製造法
JP4220698B2 (ja) * 2001-12-10 2009-02-04 花王株式会社 皮膚外用剤
JP2005538156A (ja) * 2002-09-05 2005-12-15 ガルデルマ・ソシエテ・アノニム 爪塗布用溶液

Also Published As

Publication number Publication date
ES2270347T3 (es) 2007-04-01
CA2516399A1 (en) 2004-09-10
JP4842800B2 (ja) 2011-12-21
JP2011126886A (ja) 2011-06-30
US20050187186A1 (en) 2005-08-25
DE602004001393D1 (de) 2006-08-10
JP2006518743A (ja) 2006-08-17
US7476692B2 (en) 2009-01-13
WO2004075834A2 (en) 2004-09-10
EP1594488B1 (en) 2006-06-28
CA2516399C (en) 2013-05-14
MXPA05008860A (es) 2005-10-05
ATE331507T1 (de) 2006-07-15
WO2004075834A3 (en) 2005-03-24
EP1594488A2 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
DE3686797T2 (de) Emulsionen zur verabreichung in wasser schwerloeslicher ionisierbarer basischer hydrophober arzneistoffe.
DE3686221T2 (de) Emulsionen zur parenteralen und/oder oralen verabreichung schwer wasserloeslicher ionisierbarer hydrophober arzneistoffe.
DE69218241T2 (de) Arzneistofformulierung zur parenteralen anwendung
DE69318503T2 (de) Ein definiertes lipidsystem enthaltende pharmazeutische zusammensetzung
DE69735949T2 (de) Zusammensetzung geeignet zur behandlung der pferdelahmheit
EP0864329B1 (de) Medizinische Präparation, die ein lipophiles Edelgas enthält
DE60129134T2 (de) O/w emulsion
DE69734742T2 (de) Arzneizusammensetzungen enthaltend Ascomycinderivate
DE69936911T2 (de) Propofolhaltiges arzneimittel enthaltend sulfite
EP0711556A1 (de) Intravenöse Lösungen für ein Staurosporinderivat
DE1792410B2 (de) Arzneimittelzubereitung zur intravenösen Injektion
EP0733358A2 (de) Intravenös applizierbare Nanosuspensionen
DE19509828A1 (de) Pharmazeutische Zusammensetzungen
JP2002527465A (ja) ペンテチン酸塩を含有するプロポフォール組成物
EP1684722B1 (de) Medikamentöse gezielte lokale lipolyse
JP2021535932A (ja) ニモジピン注射用組成物及びその調製方法
DE2914789C2 (cg-RX-API-DMAC10.html)
CH701081B1 (de) Zytotrope heterogene Molekularlipide (CHML), für die Behandlung von Patienten mit mehrfachem Krebs.
DE3115080A1 (de) Arzneimittel fuer die orale verabreichung und verfahren zu seiner herstellung
JPH10510267A (ja) スフィンゴ脂質の投与に適したエマルジョン及びその使用
JP2011126886A (ja) サフィンゴールの医薬組成物およびその使用方法
FI99080C (fi) Menetelmä ruoansulatuskanavan ulkopuoliseen annosteluun tarkoitettujen emulsioiden valmistamiseksi
DE3802357A1 (de) Parenterale suspensionen
EP0336000B1 (de) Ambiphile Creme
EP0535567B1 (de) Flüchtige Inhalationsnarkotika enthaltende Liposomen, ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition